Skip to main content
. 2015 Jan 27;10(11):3179–3189. doi: 10.4161/21645515.2014.983857

Figure 5.

Figure 5.

Association between vaccine-induced T-cell responses and clinical benefit defined as responding or stable disease after 3 months of vaccination (at the follow up visit). The clinical benefit rates were 14%, 33% and 75% for patients with 0, 1 and ≥ 2 TUMAP responses, respectively. 38% of Non-HBV responders and 47% of HBV responders had their disease controlled at the follow up visit.